Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 12/20 | 0.52 |
| ▸ | CA1 | P00915 | 2/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | NT5E | P21589 | 1/20 | 0.30 |
| ▸ | CA4 | P22748 | 1/20 | 0.30 |
| ▸ | CA6 | P23280 | 1/20 | 0.30 |
| ▸ | CA5A | P35218 | 1/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1219421 | 0.92 | CA2 (0.50) | CA2CA1CA12CA14 | |
| SCHEMBL1213173 | 0.86 | CA2 (0.55) | CA2CA1CA12CA14TSHR | |
| SCHEMBL1408712 | 0.77 | CA2 (0.46) | CA2CA1CA12CA14TSHR | |
| SCHEMBL19302132 | 0.76 | CA2 (0.36) | CA2CA1CA12CA14CA9 | |
| SCHEMBL293306 | 0.76 | CA1 (0.71) | CA2CA1CA12CA14CA4 | |
| SCHEMBL15522987 | 0.74 | SMN1; SMN2 (0.30) | — | |
| SCHEMBL293336 | 0.74 | CA2 (0.68) | CA2CA1CA12CA14CA4 | |
| Methane SCHEMBL8657931 | 0.74 | CA1 (0.68) | CA2CA1CA12CA14CA4 | |
| SCHEMBL21300546 | 0.74 | TSHR (0.43) | CA2CA1CA12CA14TSHR | |
| SCHEMBL25129256 | 0.72 | CA2 (0.65) | CA2CA1CA12CA14CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8293256-B2 | Sulfamide derivatives and cosmetic use thereof | L'OREAL (FR) | 2012-10-23 | — | — | US | disclosed |
| US-20110044918-A1 | Novel sulfamide derivatives and cosmetic use thereof | L'OREAL (FR) | 2011-02-24 | — | — | US | disclosed |
| EP-1669060-B9 | New sulfamide derivatives and their cosmetic use | OREAL (FR) | 2008-12-03 | — | — | EP | disclosed |
| EP-1669060-B1 | New sulfamide derivatives and their cosmetic use | OREAL (FR) | 2008-05-07 | — | — | EP | disclosed |
| US-20060134151-A1 | Novel sulfamide derivatives and cosmetic use thereof | L'OREAL (FR) | 2006-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110044918-A1 | Novel sulfamide derivatives and cosmetic use thereof | STS, TST, TPST2 | CA2 1701/4885CA1 4083/4885CA12 2571/4885 |
| US-20060134151-A1 | Novel sulfamide derivatives and cosmetic use thereof | STS, TST, TPST2 | CA2 1701/4885CA1 4083/4885CA12 2571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.